Cessatech announces agreement with the European Medicines Agency on a Paediatric Investigational Plan for its second asset CT002 for medical procedural sedation in children
·The Paediatric Committee (PDCO) under The European Medicines Agency (EMA) has agreed to the Paediatric Investigational Plan (PIP) for CT002 ·CT002 is the second asset in Cessatech’s pipeline that has secured a PIP aimed at ensuring the necessary data to support a future authorisation for use in children ·CT002 is developed to address the unmet medical need of a non-invasive sedative procedure for children undergoing MRI scanning or other procedures requiring sedationOn 12 September - Cessatech A/S (“Cessatech” or “the Company”) announces that EMA’s Paediatric Committee (